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Multi-Drug Resistance Proteins (MRPs) are members of the ATP binding cassette (ABC)
drug-efflux transporter superfamily. MRPs are known to regulate the efficacy of a broad
range of anti-retroviral drugs (ARV) used in highly active antiretroviral therapy (HAART)
and antibacterial agents used in Tuberculus Bacilli (TB) therapy. Due to their role in efflux
of glutathione (GSH) conjugated drugs, MRPs can also regulate cellular oxidative stress,
which may contribute to both HIV and/or TB pathogenesis. This review focuses on
the characteristics, functional expression, and modulation of known members of the
MRP family in HIV infected cells exposed to ARV drugs and discusses their known
role in drug-inefficacy in HIV/TB-induced dysfunctions. Currently, nine members of the
MRP family (MRP1-MRP9) have been identified, with MRP1 and MRP2 being the most
extensively studied. Details of the other members of this family have not been known
until recently, but differential expression has been documented in inflammatory tissues.
Researchers have found that the distribution, function, and reactivity of members of MRP
family vary in different types of lymphocytes and macrophages, and are differentially
expressed at the basal and apical surfaces of both endothelial and epithelial cells.
Therefore, the prime objective of this review is to delineate the role of MRP transporters
in HAART and TB therapy and their potential in precipitating cellular dysfunctions
manifested in these chronic infectious diseases. We also provide an overview of different
available options and novel experimental strategies that are being utilized to overcome the
drug resistance and disease pathogenesis mediated by these membrane transporters.
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The Role of MRPs in Decreasing Therapeutic Efficacy of HIV-1/TB
Drugs
Highly active antiretroviral therapy (HAART) has radically changed the clinical outcome of HIV
through a substantial reduction of both mortality and morbidity. HAART is responsible for a 50%
reduction in acquired immunodeficiency syndrome (AIDS) mortality rates. Furthermore, HAART
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has reduced maternal—infant transmission rates, decreased rates
of opportunistic infections, and has led to a 40–50% reduction in
the incidence of HIV associated dementia (Hayashi et al., 2006).
HAART uses a combination of drugs that typically includes two
different nucleoside reverse transcriptase inhibitors (NRTI), a
non-nucleoside reverse transcriptase inhibitor (NNRTI) and a
protease inhibitor (PI) or integrase inhibitor (INST). Both NRTIs
and NNRTIs prevent the reverse transcription of HIV. INSTs
inhibits the integration of HIV’s DNA into the DNA of the
infected cell. Lastly, PI’s prevent the production of mature virions
(Panel on Antiretroviral Guidelines for Adults and Adolescents,
2009). Despite the success of HAART, difficulties with this
treatment strategy have emerged. Long-term side effects, sub-
optimal drug potency, viral resistance, and the need for near-
perfect adherence to therapy remain major barriers to achieve
full and long-term viral suppression (Van Vaerenbergh, 2001).
Viral resistance is a particularly challenging problem, as 30–50%
of all individuals receiving HAART fail to respond to the
drugs due to the development of drug resistance mechanisms.
Thus, preventing possible escape of antiretroviral drugs by the
viral population is essential for the efficient HAART. The viral
infection depends on cellular factors at their site of action. In
particular, two factors have been proposed: (i) the defective
intracellular metabolism of nucleoside reverse transcriptase
inhibitor (NRTI) in target cells; and (ii) the altered uptake
and eﬄux of NRTI and protease inhibitor (PI) by cellular
transporter molecules (Turriziani et al., 2003). Our previous
study demonstrated that HIV-1 alone and HIV-1 in combination
with a HAART drug, such as saquinavir, can significantly increase
the drug eﬄux function of P-glycoprotein (P-gp) (Roy et al.,
2012).
Approximately one third of the HIV-1 positive patients are
also infected with TB (Ritchie et al., 2014). There is limited
evidence that early intervention with HAART results in a
better outcome in TB infection of dual infected patients (Yan
et al., 2015). It has been suggested that HIV infection impairs
host immune response to TB due to an over excitation of
cytokine milieu in the co-infected host (Chetty et al., 2014).
The overexpression of ABC transporter pump in HIV-1 and
TB infection is associated with therapeutic failure. Since the
discovery of ABC transporters, pharmacological ABC inhibitors
have been explored as therapeutic targets with limited success
(Sosnik, 2013). In this regard, a long acting treatment option is an
absolute necessary to combat this disease. Some of the variability
in patient response to anti-HIV and anti-TB therapeutics is due
to the effect of single nucleotide polymorphisms (SNPs) on drug
metabolism and drug transporter genes. It is known that SNPs
in some genes that code for P450 and UGT enzymes play a major
role in the altered expression and function ofMRPs and P-gp; this
is partly responsible for the inter-individual differences in efficacy
and toxicity of anti-HIV and anti-TB therapeutics (Michaud
et al., 2012). For instance, one study found that patients with
naturally occurring mutation CYP2B6∗6 of the CYP2B6 gene
possessed higher plasma concentrations of the HAART drug,
efavirenz (Tsuchiya et al., 2004).
Multi-drug resistant proteins are part of the ABC superfamily
of proteins that play an important role in the defense of cells
against a wide range of xenobiotics. This family comprises a
broad range of proteins found in organisms from bacteria to
humans, and transport structurally diverse substances, such as
ions, amino acids, sugars, peptides, and proteins across biological
membranes. These drug eﬄux transporters have been implicated
in the development of multi-drug resistance (MDR) (Figure 1).
Cells selected for resistance to a cytotoxic drug may become
cross resistant to a variety of drugs with different structures and
cellular targets. MDR was thought to result exclusively from
increase in P-gp activity encoded by the human MDR1 gene.
However, researchers discovered that several cell lines selected for
resistance did not show an increase in P-gp, yet became resistant
to a range of natural product drugs (Zaman et al., 1994). In
one of these non-P-gp MDR lines, the H69AR small cell lung
carcinoma line found amplification and increased expression of
a novel gene, the MRP (Cole et al., 1992). The overexpression
of MRP has since been observed in several cell lines. Moreover,
the subcellular location of MRP did not seem to be similar
to that of a plasma membrane transporter, such as P-gp. This
190KDa protein was found mainly in the endoplasmic reticulum
rather than in the plasma membrane (Zaman et al., 1994). The
discovery of MRP1 facilitated the discovery of eight more genes
within the MRP family of which at least six (MRP2, MRP3,
MRP4, MRP5, MRP6, and MRP8) are potentially involved in
mediating drug resistance (Leslie et al., 2005). Noteworthy, breast
cancer resistance protein (BCRP)—a transporter of the ABC
superfamily—also acts to defend against toxins and xenobiotics
by facilitating the excretion and limiting the absorption of
potentially toxic substrate molecules. Known sites of BCRP
expression include, the gut, bile canaliculi, placenta, testis, and
brain (Natarajan et al., 2012).
Both P-gp and MRP1 are ATP dependent transporters.
A common structural feature between P-gp and MRP1 is
glycosylation (Boumendjel et al., 2005). P-gp transports
structurally diverse drugs including, anthracyclines
(doxorubicin, daunorubicin), vinca alkaloids (vinblastine,
FIGURE 1 | Schematic representation of the role of MRP efflux
transporters in HIV-1 and TB therapy.
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vincristine), paclitaxel, epipodophyllotoxins (etoposide,
teniposide) and other compounds. MRP is remarkably similar
to the drug transporting P-gp in its mode of action. Like P-gp,
MRP1 (i) can promote resistance to various hydrophobic
drugs, (ii) is located in the plasma membrane, as well as in the
endoplasmic reticulum, (iii) can decrease drug accumulation
in the cell through permeabilization of the plasma membrane,
and (iv) can increase the eﬄux of drugs from cells (Zaman
et al., 1994). Nevertheless, there are also important differences
between P-gp and MRP1 with respect to the drugs that they
transport and interact with. While P-gp drug eﬄux transporters
can only target and transport hydrophobic drugs, MRP can
transport hydrophilic molecules and even organic anions.
MRP1 acts as a transporter of organic anions—particularly
of glutathione conjugates—and can work in concert with the
glutathione detoxification system (Váradi and Sarkadi, 2003).
Studies involving MRPs are complicated by the presence of
multiple biochemical pathways that can be utilized by the MRPs
eﬄux system to extrude various compounds. In particular,
glutathione S-transferases or GSH/GST detoxification system is
known to act in concert with MRPs, as many MRPs substrates
are GSH-dependent (Evers et al., 2000). These substrates (i.e.,
vinblastine, doxorubicin) are either co-transported with GSH,
or first conjugated with GSH, and then transported as the GSH
conjugate. MRPs can also transport neutral drugs conjugated
with glutathione, glucuronide, or sulfate, and anticancer agents
that are not metabolized to glutathione conjugates by co-
transport with receded GSH. Usually GSH conjugation occurs
either spontaneously or through catalysis by a glutathione S-
transferase andmay contribute to theMDR phenotype. However,
it is not well understood how and why GSH doesn’t interact
with MRP1 (Boumendjel et al., 2005). The known substrates for
BCRP include, methotrexate, mitoxantrone, and topoisomerase
I inhibitors of topotecan and irinotecan (Kawabata et al., 2003).
MRP1 is ubiquitously expressed throughout the body, while
MRP2 is most highly expressed in the liver, kidney and gut. The
preferred substrates for MRP1 and MRP2 are organic anions,
e.g., drugs conjugated with glutathione, glucuronate, or sulfate.
Despite a similar substrate preference, MRP1 and MRP2 have
distinct functions due to differences in their expression pattern.
MRP1 is a major eﬄux pump that excretes a diverse range of
endogenous substances and xenobiotics (He et al., 2011). MRP2
is involved in the excretion of bilirubin glucuronides into the
bile and xenobiotics into the intestinal lumen. The next member
of the family, MRP3, is concentrated in the liver and adrenal
cortex and possesses a high structural similarity to MRP1 (58%).
MRP3 has an affinity for glutathione and glucuronate conjugates,
although its drug resistance capabilities are significantly less
than either MRP1 or MRP2. In addition, MRP3 can transport
monoanionic bile acids, which has led to speculation that MRP3
protein may help detoxify hepatocytes of bile acids (Kruh and
Belinsky, 2003). MRP4 is predominately found in the kidney
and lungs, whereas MRP5 is ubiquitously expressed. MRP4 and
MRP5 act as organic anion transporters. Furthermore, both
MRP4 and MRP5 are thought to mediate the urinary eﬄux of
cAMP and cGMP (Maher et al., 2005). MRP4 was also found to
play a significant role in the urinary excretion of furosemide and
hydrochlorothiazide (Hasegawa et al., 2007). MRP6-MRP9 drug
eﬄux transporters have been identified more recently and less is
known about their function, localization and regulation. MRP6
is an organic anion transporter that is distributed most highly in
the liver and kidney. While MRP6 does not play a role in drug
resistance, it may be a constitutive “housekeeping” transporter of
normal and abnormal hepatocytes (Madon et al., 2000). MRP7 is
a lipophilic anion transporter primarily found in the heart, liver,
skeletal muscle, and kidney. MRP7 has a substrate range similar
to MRP1-MRP4 and is involved in phase III (cellular extrusion)
of detoxification (Chen et al., 2003). MRP8 is an organic anion
transporter that is highly expressed in the liver and has been
associated with drug resistance to anti-cancer drugs. The precise
function of MRP8 is currently unknown. Finally, MRP9 is known
to be highly expressed in the testes and in breast tissue, but the
preferred substrate and function of MRP9 is currently unknown
(Yabuuchi et al., 2002).
Evidence of MRP in Efflux of Anti-HIV
Agents
HIV Protease Inhibitors (HPIs) are key components in HAART
(O’Meara et al., 2001; Bachmeier et al., 2005). Given the impact
of P-gp in vivo on HPIs pharmacology, it is important to
assess, whether other drug transporters of the ABC family can
also efficiently transport HPIs. For instance, HPIs are known
to be substrates for MRP1 and MRP2. This may affect their
pharmacological disposition and thus their therapeutic efficiency
(Huisman et al., 2002). MRP1 is found throughout the human
body and may have a role in resistance as it is also found
in most tumors (Table 1). Without effective and specific MRP
inhibitors, it’s not possible to analyze the contribution of MRP1
to resistance by use of intervention studies, in which anticancer
drugs transported by MRP1 are combined with an inhibitor of
MRP1 (Borst et al., 2000). MRP2 is responsible for the transport
of the majority of tested HPIs. This has essential implications
for the pharmacological use of HPIs. In a rat model, MRP2 was
shown to contribute to hepatobiliary, renal and direct intestinal
excretion of its substrates, and to limit their oral bioavailability.
It is highly likely that MRP2 reduces the plasma levels of
HPIs through the same mechanism (Huisman et al., 2002). Of
note, even within the same cell type, the resistance phenotype
conferred by the expression of human MRP1 and mouse MRP1
differ substantially. In general, the resistance profiles of the
various selected drugs were similar. It has been found that
moderate to high level resistance occurs (depending on the cell
line) to various drugs when MRP1 is over-expressed. While the
resistance phenotype conferred by MRP1 expression may be
influenced by the type of cell in which it is expressed, much of
this variability is certainly the result of the complexity of cellular
responses to drug selection (Hipfner et al., 1999).
Most of the MRP1-mediated eﬄux is dependent on GSH.
Thus, decreasing the intracellular level of GSH with L-
buthionine-S, R-sulfoximine (BSO) and the inhibition of GSH
synthesis reduces transport of Daunorubicin, Dosorubicin,
Etoposide, and Vincristine in cells with over-expressed MRP1.
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TABLE 1 | Distribution, physiologic function, and substrate specificity of human multidrug resistance proteins.
MRPs Location Physiologic function Substrate specificity References
MRP1 Ubiquitous Efflux of a diverse range of endogenous
substances and xenobiotics
Organic anions and steroid
conjugates
He et al., 2011
MRP2 Liver, kidney, and gut Excretion of bilirubin glucuronides into bile
and xenobiotics into the intestinal lumen
Organic anions He et al., 2011
MRP3 Liver, adrenal, pancreas, kidney, and
gut
Acts as a protective mechanism when
MRP2 is absent or nonfunctional. Also
plays an important role in the
enterohepatic circulation of endogenous
compounds such as bile salts
Organic anions and monoanionic bile
acids
Kruh and Belinsky, 2003
MRP4 Prostate, lung, muscle, pancreas,
testis, ovary, bladder, and gallblader
Mediation of the extrusion of cAMP and
cGMP in urine
Organic anions, cAMP, cGMP, and
steroid conjugates
Maher et al., 2005
MRP5 Ubiquitous Mediation of the extrusion of cAMP and
cGMP in urine
Organic anions and cyclic nucleotides Maher et al., 2005
MRP6 Liver and Kidney Plays a vital constitutive housekeeping role
in normal and abnormal hepatocytes.
Lipophilic anions Madon et al., 2000
MRP7 Heart, liver, skeletal muscle, and
kidney
Involved in phase III (cellular extrusion) of
detoxification
Lipophilic anion Chen et al., 2003
MRP8 Liver Unknown Cyclic nucleotides Yabuuchi et al., 2002
MRP9 Breast tissue and testis Unknown Unknown Yabuuchi et al., 2002
These compounds are not known to conjugate with GSH.
This implies that GSH is necessary for a possible co-transport
mechanism or plays a role as a cofactor for substrate transport.
It also seems that the transport efficiency is impacted by the
hydrophobicity of the substrate. Hydrophobic substrates, such
as derivatives of verapamil, enhance GSH transport of MRP1
more efficiently than hydrophilic derivatives. A direct interaction
with drug binding sites is only one way that GSH affects MRP1.
Drug transport may be also impacted by the increased ATP
binding and ATPase activity caused by GSH. MRP2 and MRP3
also appear to be similar to MRP1 in the mechanism of GSH-
mediated transport. GSH appears to be substrates for both MRP4
and MRP5 as well, but unlike other members of the MRP
family, they also transport cyclic nucleotides cAMP and cGMP
and even antiretroviral drugs 9-(2-phosphonylmethoxyethyl)
adenine, which is independent of GSH (Ballatori et al., 2005).
MRP1 is not an efficient transporter for sequinavir, ritonavir
and indinavir (Huisman et al., 2002). Moreover, nelfinavir and
amprenavir do not appear to be strong substrates for MRP1. The
rank order of potency for MRP-related drug eﬄux transport was
nelfinavir > ritonavir > sequinavir > amprenavir > indinavir
(Bachmeier et al., 2005). Although interaction between the HIV-
1 protease inhibitor, P-gp, and MRP drug eﬄux transporters has
been reported, a quantitative assessment as to the extent of this
interaction has not been performed, since this group of drugs
is commonly utilized in combination with other HIV-1 protease
inhibitor or various antiviral agents as part of a HAART regimen
(Bachmeier et al., 2005).
HAART Induced Oxidative Stress
It has been shown that various conditions caused by different
genetic or environmental insult may have one common
molecular basis, namely, oxidative stress. Recent studies have
indicated that HIV and TB infections are associated with
oxidative stress (Tyagi et al., 2015). HIV increases the
level of reactive oxygen species (ROS) within infected cells
and the plasma/serum levels of lipid peroxidation products,
malondialdehyde, and hydrogen peroxide. This is manifested in
ongoing oxidative stress in HIV infected patients. The markers of
oxidative stress previously stated can be detected in HIV infected
T-cells, peripheral monocytes, and in the brain. Noteworthy,
the brain is the main source of oxidative stress, as it is rich
in polyunsaturated fatty acids, accumulates redox metal ions,
consumes a large amount of inspired oxygen, is relatively low
in antioxidants, and is composed largely of non-mitotic cells
(Aksenova et al., 2005).
In HIV infection, oxidative stress caused by ROSmay enhance
viral replication by activating nuclear transcription factors, such
as NF-κB, ultimately leading to viral gene expression. While the
virus itself increases oxidative stress levels through replication,
control of the virus with antiretroviral therapy leads to a similar
increase in oxidative stress. HIV-infected subjects exhibited
significantly higher levels of oxidative stress and DNA damage
as measured by higher levels of modified lymphocyte DNA
bases and lower activity levels of antioxidant enzymes than
in HIV negative subjects (Lanzillotti and Tang, 2005). Free
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radicals can damage DNA through a number of mechanisms
including direct alteration of base pairs resulting in miscoding.
Some of these changes can be pre-mutagenic. Miscoding can
also result in a decrease in critical proteins within neurons.
DNA analyses of HIV infected lymphocytes demonstrated
heightened hydroxylation of guanine and increased presence of
thymidine/uridine residues when compared with lymphocytes
from the control group (Valcour and Shiramizu, 2004). Recent
reports continue to point to the mitochondria as the target
for toxicity (Matarrese et al., 2005). The prevalence of these
symptoms is worsened in individuals suffering from AIDS. The
effect of oxidative stress as a consequence of mitochondrial
toxicity may amplify some pathophysiological and phenotypic
events during infection (Gil et al., 2005). Certain factors, such
as immune activation due to HIV/co-infection and HAART
increase the expression of HIV proteins, Tat, Nef, Vpr, and gp120.
This induces oxidative stress, which can disrupt cell structure,
alter blood brain barrier (BBB) defenses, and effect aberrant
signaling and apoptosis (Perl and Banki, 2000; Valcour and
Shiramizu, 2004). Oxidative stress plays a central role in the
neurotoxicity caused by Tat and gp120. It has been confirmed that
antioxidants can protect against the neural cell damage mediated
by these virotoxins (Aksenova et al., 2005).
ROS produced by the host is critical for controlling TB
infection. Unfortunately, very little is known about the dynamic
response of TB to endogenous oxidative stress (Tyagi et al., 2015).
Macrophage intracellular protein like NOD plays an important
role in controlling inflammatory and ROS response in the cells.
A proper homeostasis of ROS is essential for the persistence and
survival of TB (Kumar et al., 2011). It is therefore suggested that
anti-TB drug that induces ROS are at a greater risk of toxicity
because of poor antioxidant mechanisms (Walubo et al., 1995).
Role of MRPs in Cellular Oxidative Stress
The potential importance of MRP1 in HIV infection relates
to at least two crucial factors. The first is that HPIs and
nucleoside analogs are both substrates for P-gp and MRP1.
The second is that MRP1 plays a role in the defense against
oxidative stress. In patients infected with HIV-1, increases in
oxidative stress have been found to increase the transcription of
HIV-1 by activating nuclear factor kB (NF-kB). The activation
of MRP1 may play an important role in partial restoration
under HAART (Lucia et al., 2005). MRP1 engenders resistance
through the removal of drug conjugates from cells, which
occurs indirectly through the transport of anionic phase II
biotransformation products conjugated to GSH or other small
molecules (Hipfner et al., 1999). The substrate with the greatest
affinity for metabolites of exogenous molecules transported by
MRP1 is GSH conjugated aflatoxin B1.The endo and exo epo-
oxides formed are detoxified by GST catalyzed conjugation to
GSH. Following these formations, they are eliminated from the
cell. Evidence of this process can be found in several transfection
studies, which have shown that MRP1 and GST affect drug
resistance through synergistic action (Hipfner et al., 1999). While
MRP1 typically requires GSH in order to transport drugs out of
cells, some drugs such as antimetabolites (MTX) can be removed
from cells without GSH. (Létourneau et al., 2005). It was once
thought that MRP1 simply transported glutathione S conjugates.
However, we now know that the interplay between GSH and
MRP1 is more complicated and only partly understood (Ballatori
et al., 2005). GSH not only acts as a substrate of MRP1, but
also has important roles in the overall transport mechanism.
Furthermore, GSH plays a role in stimulating the transport of
certain compounds by MRP1 (Létourneau et al., 2005).
Accelerated Drug Resistance to HAART
from Drugs of Abuse
Within a few days of infection HIV infected macrophages are
extraverted through the BBB. Once inside the central nervous
system (CNS), the neurotoxic effects of HIV are manifested
indirectly through the release of viral proteins, such as gp120,
from infected microglial cells. The increased expression of gp120
has been shown to cause neuronal damage both through the
induction of oxidative stress and greater HIV penetration into
the CNS due to alterations in the permeability of the BBB.
Glial cell cultures treated with gp120 showed increased levels of
ROS, apoptosis, lipid per oxidation, and a loss of dopaminergic
neurons. In addition, these cells were found to have increased
expression and activity of MRPs as shown in Figure 2 (Silverstein
et al., 2012).
Cocaine and methamphetamine are known to accelerate HIV-
associated neurocognitive disorders (HAND) through several
factors. These drugs of abuse (DOA) enhance HIV-1 penetration
into the CNS through (i) increased permeability of the BBB, (ii)
increases in the transmigration of macrophages through the BBB
(Zhang et al., 1998), and (iii) by exacerbating the neurotoxic
effects of gp120 through decreased cell viability, an increased
level of apoptotic cells, and increased expression of caspase-
3, Bax, and ROS. Both of these DOA and gp120 were found
to independently generate oxidative stress through overlapping
signal transduction pathways (p38MAPK, NF-kB, etc.). When
administered together, both cocaine and methamphetamine
interact synergistically with gp120 to produce greater oxidative
stress than is produced when administered separately (Silverstein
et al., 2012).
HIV-infected individuals who suffer from drug addiction also
experience accelerated resistance to HAART drugs (Silverstein
et al., 2012). It is known that astrocytes undergoing oxidative
stress rapidly release glutathione disulfide via MRP1 transporters
(Hirrlinger et al., 2001). MRP1 can eﬄux all of the constituents
of HAART from intracellular compartments (Eilers et al., 2008).
Thus, we suspect that the additional oxidative stress placed on the
brain through the abuse of cocaine/methamphetamine increases
MRP1 expression at the BBB, thereby, accelerating resistance to
HAART drugs.
Role of MRPs in TB Infection and Therapy
TB is a major cause of morbidity and mortality for individuals
infected with HIV. The complications from drug-drug
interactions for concomitmant therapy of both conditions have
been reviewed (Gengiah et al., 2011; Regazzi et al., 2014; Semvua
et al., 2015). The first-line TB drug rifampicin (RIF) is a potent
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FIGURE 2 | HIV and TB induced upregulation of reactive oxygen species (ROS) that increases MRP function. The increase in MRP mediated HIV and TB
drugs efflux eventually decreases therapeutic efficacy.
inducer of hepatic cytochrome CYP450 system, thus increasing
the rate of metabolism of antiretroviral drugs in the liver to result
in subtherapeutic antiretroviral drug concentrations (Piscitelli
and Gallicano, 2001; Semvua et al., 2015). Protease inhibitors
are known to be substrates of CYP3A4 and therefore could not
be coadministered with RIF (Gengiah et al., 2011). RIF also
increases the metabolism of integrase inhibitors by inducing
the uridine diphosphate glucuoronosyltransferase (UGT) 1A1
enzyme (Wenning et al., 2009; Regazzi et al., 2014). Altered drug
eﬄux from drug-drug interaction can also play a significant role
in drug-drug interactions in treatment of patients coinfected
with TB and HIV.
There is a large number of putative eﬄux pumps (EP)
encoded in the Mycobacterium tuberculosis genome belonging
to multiple major transporter families including the ABC-type
transporters that are homologous to human MRPs (Black et al.,
2014). DrrA (Rv2936) gene has been associated with eﬄux of
multiple drugs including RIF, isoniazid (INH), and ethambutol
(EMB) (Black et al., 2014; Li et al., 2015). Overexpression
of ABC EP system Rv1456c-Rv1457c-Rv1458c was found in
clinical isolates that are resistant to at least one of the four
first-line drugs RIF, EMB, INH, and streptomycin (STR) (Hao
et al., 2011). Increased expression of ABC transporters Rv1217c-
Rv1218c in MDR-TB has been correlated with higher minimum
inhibition concentrations (MICs) for RIF, and the overexpression
of Rv1218c was correlated with higher MICs for INH (Wang
et al., 2013). Another ABC transporter found in M. tuberculosis,
Rv0194, has also been associated with resistance to a variety of
antibiotics including STR (Danilchanka et al., 2008). Sequence
alignment of Rv0194 with human MRP2, MRP4 is shown in
Figure 3.
If human MRPs can also act as eﬄux pumps for the TB
drugs, the increased expression of MRPs in macrophages would
decrease the intracellular levels of the TB drugs (Figures 1, 2).
This would aid the evolution of TB drug tolerance (Szumowski
et al., 2013). The expression levels of MRP in the peripheral
mononuclear cells of MDR-TB patients were found to be approx.
three-fold higher than non-TB control group and TB control
group (Lian et al., 2011). This may be responsible for the
multi-drug resistance in MDR-TB patients. A study of Listeria
monocytogenes has shown that a bacterial eﬄux pump may
cooperate with macrophage MRP to reduce the antibacterial
activity of the common substrate ciprofloxacin (Lismond et al.,
2008). Moxifloxacin is a second line TB drug currently used
in novel regimens designed to decrease length of therapy
(Dawson et al., 2015). Unlike the more commonly prescribed
fluoroquinolone, ciprofloxacin, moxifloxacin accumulation is
not affected by overexpression of MRP4 in macrophages
(Michot et al., 2006). Prolonged exposure to moxifloxacin
can nevertheless result in the overexpression of macrophage
transporters including P-gp, MRP2, and MRP4 resulting in the
drug-drug interaction (Vallet et al., 2011).
Novel Approaches to Overcome Multi-drug
Resistance to HIV and TB Therapy
Since the emergence of HIV, decades of research has focused on
the treatment of AIDS to combat the virus. These treatments
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MRP2            FSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS 240 
MRP4            --MLPVYQEVKPNPLQDANLCSRVFFWWLNPLFKIGHKRRLEEDDMYSVLPEDRSQHLGE 58 
Rv0194          ---------------------MRTNCWWRLSGYVMRHRRDLLLG---------------- 23 
                                           *  .     ::* *
MRP2            TKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRD----TY 356 
MRP4            ------KPSLTRAIIKCYWKSYLVLGIFTLIEESAKVIQPIFLGKIINYFENYDPMDSVA 130 
Rv0194          -------------------------FGAALAGTVIAVLVPLVTKRVIDDAIAAD------ 52 
                                             *      .: * .   :*.     *
MRP2            LWIGYLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYT 416 
MRP4            LNTAYAYATVLTFCTLILAILHHLYFYHVQCAGMRLRVAMCHMIYRKALRLSNMAMGKTT 190 
Rv0194          HRPLAPWAVVLVAAAGATYLLMYVRRYYGGRIAHLVQHDLRMDAFQALLRWDGRQQDRWS 112 
                       * :*  .:    :            .  ::  :    ::  *  ..    . : 
MRP2            VGETVNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPI 476 
MRP4            TGQIVNLLSNDVNKFDQVTVFLHFLWAGPLQAIAVTALLWMEIGISCLAGMAVLIILLPL 250 
Rv0194          SGQLIVRTTNDLQLVQALLFDVPNVLRHVLTLLLGVAVMTWLSVPLALLAVLLVPVIGLI 172 
                 *: :   : * : .  :   :  :    *  :    .:        * .: :: ::  : 
MRP2            NAILSTKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNL 536 
MRP4            QSCFGKLFSSLRSKTATFTDARIRTMNEVITGIRIIKMYAWEKSFSNLITNLRKKEISKI 310 
Rv0194          AHRSRRLLAAATHCAQEHKAAVTGVVDAAVCGIRVVKAFGQEERETVKLVTASRALYAAQ 232 
                         :        .      ::  : **:::* :. *      : .  :
MRP2            LAFSQLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLS-M 595 
MRP4            LRSSCLRGMNLASFFSASKIIVFVTFTTYVLLGS--VITASRVFVAVTLYGAVRLTVTLF 368 
Rv0194          LRVARLNAHFGPLLQTLPALGQMAVFALGGWMAAQGSITVGTFVAFWACLTLLARPACDL 292 
                *  : *.      :   . :  ...*:    : :   : .   ..  :    :  .   : 
MRP2            LPMMISSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEA-TV 654 
MRP4            FPSAIERVSEAIVSIRRIQTFLLLDEISQRNRQLPSDGKKMVHVQDFTAFWDKASETPTL 428 
Rv0194          AGMLTIAQQARAGAVRVLELIDSRPTLVDGTKPLSPEARLSLEFQRVS--FGYVADRPVL 350 
                             : . ::       :         :    :...  :  :   ::  .: 
MRP2            RDVNLDIMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKG-------------TT 701 
MRP4            QGLSFTVRPGELLAVVGPVGAGKSSLLSAVLGELAPSHGLVSVHG-------------RI 475 
Rv0194          REISLSVRAGETLAVVGAPGSGKSTLASLATRCYDVTQGAVRIGGQDVRELTLDSLRSAI 410 
                : :.: : .*: :**:*. *:***:* *         :* : : *
MRP2            AYVPQQSWIQNGTIKDNILFG-TEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGIN 760 
MRP4            AYVSQQPWVFSGTLRSNILFG-KKYEKERYEKVIKACALKKDLQLLEDGDLTVIGDRGTT 534 
Rv0194          GLVPEDAVLFSGTIGANIAYGRPDATPEQIATAARAAHIEEFVNTLPDGYQTAVGARGLT 470 
                . *.::. : .**:  ** :*  .   ::   . .*. :   :: * .*  : :* :* . 
MRP2            LSGGQKQRISLARATYQNLDIYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTH 820 
MRP4            LSGGQKARVNLARAVYQDADIYLLDDPLSAVDAEVSRHLFELCICQ--ILHEKITILVTH 592 
Rv0194          LSGGQRQRIALARALLHQPRLLIMDDPTSAVDAVIECGIQEVLREA---IADRTAVIFTR 527 
                *****: *: ****  ::  : ::*** ***** :   : :        :  :  ::.*: 
MRP2            SMHFLPQVDEIVVLGNGTIVEKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEE 880 
MRP4            QLQYLKAASQILILKDGKMVQKGTYTEFLKSGIDFGSLLK--------------KDNEES 638 
Rv0194          RRSMLTLADRVAVLDSGRLLDVGTPDEVWERCPRYRELLSP------------------- 568 
                    *  ...: :* .* ::: *:   .      : . *.
FIGURE 3 | Continued
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MRP2            EDDDYGLISSVEEIPEDAASITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLK 940 
MRP4            EQ------------PPVPGTPTLRN-----RTFSESSVWS---QQSSRPSLKDGALESQD 678 
Rv0194          -------------APDLADDLVVAE-----RSPVCRPVAGLGTKAAQHTNVHNPGPHDHP 610 
                              *  .   .: .     *:    .  .     : : .::    ..
MRP2            EDEELVKGQKLIKKEFIETGKVKFSIYLEYLQA-IGLFSIFFIILAFVMNSVAFIGSNLW 999 
MRP4            TENVPVT----LSEENRSEGKVGFQAYKNYFRAGAHWIVFIFLILLNTAAQVAYVLQDWW 734 
Rv0194          PGPDPLRR---LLREFR--GPLALSLLLVAVQTCAGLLPPLLIRHGIDVGIRRHVLSALW 665 
                     :     : .*    * : :.     .::    :  :::          .: .  * 
MRP2            LSAWTSDSKIFNSTDYPAS------QRDMRVGVYGALGLAQGIFVFIAHFWSAFGFVHAS 1053 
MRP4            LSYWANKQSMLNVTVNGGGNVTEKLDLNWYLGIYSGLTVATVLFGIARSLLVFYVLVNSS 794 
Rv0194          WAALAG----------------------------TATVVIRWVVQWGSAMVAGYTGEQVL 697 
                 :  :.                             .  :   :.     :   :   :
MRP2            NILHKQLLNNILRAPMRFFDTTPTGRIVNRFAGDISTVDDTLPQSLRSWITCFLGIISTL 1113 
MRP4            QTLHNKMFESILKAPVLFFDRNPIGRILNRFSKDIGHLDDLLPLTFLDFIQTLLQVVGVV 854 
Rv0194          FRLRSVVFAHAQRLGLDAFEDDGDAQIVTAVTADVEAIVAFLRTGLVVAVISVVTLVGIL 757 
                  *:. ::    :  :  *:    .:*:. .: *:  :   *   :   :  .: ::. : 
MRP2            VMICMATPVFTIIVIPLGIIYVSVQMFYVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVI 1173 
MRP4            SVAVAVIPWIAIPLVPLGIIFIFLRRYFLETSRDVKRLESTTRSPVFSHLSSSLQGLWTI 914 
Rv0194          VALLAIRARLVLLIFTTMPVLALATWQFRRASNWTYRRARHRLGTVTATLREYAAGLRIA 817 
                       . :.: :..   :       :  :*.   *      ..: : : .   **
MRP2            RAFEHQQRFLKHNEVRIDTNQKCVFSWITSNRWLAIRLELVGNLTVFFSALM--MVIYRD 1231 
MRP4            RAYKAEERCQELFDAHQDLHSEAWFLFLTTSRWFAVRLDAICAMFVIIVAFG--SLILAK 972 
Rv0194          QAFRAEYRGLQSYFAHSDDYRRLGVRGQRLLALYYPFVALLCSLATTLVLLDGAREVRAG 877 
                :*:. : *  :   .: *   .  .            :  :  : . :  :     :
MRP2            TLSGDTVGFVLSNALNITQTLNWLVRMTSEIETNIVAVERITEYTKVENEAPWVTDKRPP 1291 
MRP4            TLDAGQVGLALSYALTLMGMFQWCVRQSAEVENMMISVERVIEYTDLEKEAPWEYQKRPP 1032 
Rv0194          VISVGALVTYLLYIELLYTPIGELAQMFDDYQRAAVAAGRIRSLLSTRTPS----SPAAR 933 
                .:. . :   *     :   :   .:   : :   ::. *: .  . .. :    .  .
MRP2            PDWPSKGKIQFNNYQVRYRPELDLVLRGITCDIGSMEKIGVVGRTGAGKSSLTNCLFRIL 1351 
MRP4            PAWPHEGVIIFDNVNFMYSPGGPLVLKHLTALIKSQEKVGIVGRTGAGKSSLISALFRLS 1092 
Rv0194          PVGTLRGEVVFDAVHYSYRTREVPALAGINLRIPAGQTVVFVGSTGSGKSTLIKLVARFY 993 
                *  . .* : *:  :  * .    .*  :.  * : :.: .** **:***:* . : *:
MRP2            EAAGGQIIIDGVDIASIGLHDLREKLTIIPQDPILFSGSLRMNLDPFN-NYSDEEIWKAL 1410 
MRP4            EPEG-KIWIDKILTTEIGLHDLRKKMSIIPQEPVLFTGTMRKNLDPFN-EHTDEELWNAL 1150 
Rv0194          DPTHGTVRVDGCDLREFDVDGYRNRLGIVTQEQYVFAGTVRDAIAYGRPDATDAQVERAA 1053 
                :.    : :*     .:.:.. *::: *:.*:  :*:*::*  :   . : :* :: .*
MRP2            ELAHLKSFVASLQLGLSHEGTEAGGNLSIGQRQLLCLGRALLRKSKILVLDEATAAVDLE 1470 
MRP4            QEVQLKETIEDLPGKMDTELAESGSNFSVGQRQLVCLARAILRKNQILIIDEATANVDPR 1210 
Rv0194          REVGAHPMITALDNGYLHQVTAGGRNLSAGQLQLLALARARLVDPDILLLDEATVALDPA 1113 
                . .  :  :  *      : : .* *:* ** **:.*.** * . .**::****. :*
MRP2            TDNLIQTTIQNEFAHCTVITIAHRLHTIMDSDKVMVLDNGKIIECGSPEELLQIP-GPFY 1529 
MRP4            TDELIQKKIREKFAHCTVLTIAHRLNTIIDSDKIMVLDSGRLKEYDEPYVLLQNKESLFY 1270 
Rv0194          TEAVVQRATLTLAARRTTLIVAHGLAIAEHADRIVVLEHGTVVEDGAHTELLAAGGHYSR 1173 
                *: ::*       *: *.: :** *    .:*:::**: * : * .    **
FIGURE 3 | Sequence Alignment of MRP2, MRP4, Rv0194 with ClustalW2. http://www.ebi.ac.uk/Tools/msa/clustalw2/.
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have transformed the outcome of AIDS from a subacute illness
with near certain death to a chronic disease with hope for long
term survival for many patients. Present research has centered
in on the long term survival of HIV in the body, the side
effects of the treatment, and long term consequences of infection.
Several studies related to theMRP inhibition—mainlyMRP1 and
MRP2—have found that even short term inhibition results in
unacceptable levels of toxicity (Higgins, 2007).
One clinical trial found that selenium supplementation inHIV
positive subjects reduced hospitalization rates and declines in
CD4+ cell counts as compared to subjects who were not given
the supplement. While selenium is an integral part of glutathione
peroxidase—amajor protective enzyme against oxidative stress—
it also plays an important role in immunologic function. During
viral infection, it appears as though the Th1 series of cytokines
is necessary for an appropriate cellular defense. These include
Interleukin 2 (IL 2) and Interferon γ (IFN-γ). Several studies
have found that as HIV infection progresses, IL-2 and IFN-γ
levels decline, while Th2 cytokines, specifically IL-4, IL-6, and
IL-10 increase. In in vitro studies, selenium supplementation has
been shown to up-regulate IL-2 and thus increase the activation,
proliferation, and differentiation of T-helper cells (Lanzillotti and
Tang, 2005).
Usually natural product derived drugs enter cells by passive
diffusion. Oxidation and/or conjugation can inactivate these
amphipathic drugs. Conjugation alone is not sufficient to get rid
of the drugs. The conjugated drugs are no longer hydrophilic
due to the attachment of GSH, and therefore, they are unable
to leave the cell via passive diffusion. As the drug continues to
enter the cell, and get conjugated to the GSH, it will accumulate
to excessive concentration unless get exported by a specific
export pump, GS-X pump (Borst et al., 2000). The profound
drug-drug interaction between immunosuppressive drugs and
a protease inhibitor have been observed. Without the use of
protease inhibitors, HAART with nucleoside or non-nucleoside
reverse transcriptase inhibitors has been shown to produce less
significant drug-drug interactions. Thus, it is vital to understand
these potential pharmacodynamic drug-drug interactions in
order to avoid drug toxicity and lack of efficacy (Izzedine et al.,
2004). The HAART-inducedmitochondrial toxicity has indicated
particularly dideoxynucleotide reverse transcriptase inhibitor
partially through inhibition of mitochondrial DNA polymerase
gamma, and this mitochondrial damage is associated with acute
and chronic viral infection (Valcour and Shiramizu, 2004). It
has been established that changes in the ATP production or
mitochondrial metabolism of cancer cells impacts drug resistance
and redox balance (Lucia et al., 2005).
Nanomedical Applications toward
Multi-drug Resistance to HIV and TB
Therapy
For several widely used antiretrovirals, for example efavirenz,
the drug resistance is engendered through poor bioavailability
at anatomical viral reservoir sites. One of these sites, the CNS,
is vital to HIV persistence, and acts as a major barrier to
successful HIV eradication. Following antiretroviral therapy,
HIV persists in the long-lived cells of the CNS as a latent
infection. At sub-therapeutic antiretroviral levels, the CNS
reservoir provides opportunity for the virus to evolve and
enhance its fitness (Gomes et al., 2014). Most antiretroviral
drugs cannot reach these sites in therapeutic doses, because
they are either unable to penetrate the CNS, or they are
excluded by eﬄux transporters in the BBB. In addition, the
long-term presence of HIV in the CNS has been associated
with neurocognitive and motor disorders (Gomes et al., 2014).
Rates of HIV associated neurocognitive impairment will likely
rise in the coming years as anti-HIV therapies continue to
extend the lifespan of patients. Eliminating CNS reservoirs of
HIV will greatly increase the quality of life and lifespan of
seropositive individuals. Engineered nanoparticles may provide
the ability to bypass the BBB and reach these HIV reservoir sites.
Previous studies have indicated that polymeric nanoparticles
loaded with HAART drugs can cross BBB and reach the CNS
reservoir at therapeutic levels in HIV-1 infected humanized
mouse and macaque models (Dash et al., 2012; Roy et al., 2012).
It also been established that the sustained drug release provided
by these nanoformulations are more effective in controlling
viral replication than the unformulated drugs that are currently
available (Gautam et al., 2013). Therapeutic drugs conjugated
to nanodiamond may be able to overcome the restricted access
of the BBB by stealthily bypassing eﬄux transporters. These
nanoparticles should have a total size ranging from 4 to 100
nanometers in order to avoid eﬄux into the extracellular
membrane. The nanodiamond core will also increase drug
stability and prolong drug circulation time (Jarre et al., 2014).
Coating the nanoparticles with a surface stabilizer may be of
interest in achieving increased brain drug levels. In particular,
the addition of polysorbate 80—a nonionic surfactant—may
significantly enhance brain delivery. One study showed a 20-fold
increase in brain endothelial cell uptake of polysorbate 80-coated
nanoparticles compared to the uncoated nanoparticles. Increased
uptake of the coated nanoparticles is thought to result from
polysorbate 80’s adsorption of different apolipoproteins, thereby
mimicking lipoproteins on their receptor-mediated transcytosis
pathway into the CNS (Ramge et al., 2000).
Polymeric micelles were also suggested for improved
transport of drugs across the BBB and to drug-resistant
cells. These carriers consist of amphiphilic polymers that
spontaneously form nanosized aggregates when the individual
polymer chains (“unimers”) are directly dissolved in aqueous
solution (Kabanov et al., 1995) above a threshold concentration
(critical micelle concentration or CMC) and solution
temperature (critical micelle temperature or CMT). Polymeric
micelles can be utilized for the delivery of hydrophobic and
amphiphilic drugs. They offer several benefits as nanocarriers,
including, improved drug solubility, protection of drugs from
degradation, and increased drug exposure time to specific
tissues. Polymeric micelles have been evaluated in several
pharmaceutical applications as drug and gene delivery systems
(Kabanov et al., 1995; Löbenberg et al., 1998a,b; Bronich et al.,
2000; Kabanov and Alakhov, 2002; McGirt et al., 2004; Shah
and Amiji, 2006; Kabanov and Batrakova, 2008). Recently, new
Frontiers in Microbiology | www.frontiersin.org 9 September 2015 | Volume 6 | Article 948
Roy et al. MRPs in HIV and TB therapy and pathogenesis
polymer micelles-based nanosystems were developed that utilize
cross-linked ionic cores. These novel polymer micelles allow for
the encapsulation of charged therapeutic or diagnostic molecules
and resist dissociation of the micelle upon dilution (Bronich
et al., 2000).
In addition, selected polymer nanomaterials can be used for
biological response modifiers. One example of these polymer
nanomaterials is Pluronics—triblock copolymers consisting of
poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO),
(PEO-b-PPO-b-PEO), which has been found to cause various
functional alterations in cells (Batrakova and Kabanov, 2008). It
was demonstrated that a formulation of different low molecular
weight drugs, including antiretroviral drugs, into Pluronics
resulted in the improved drug transport across the BBB. The
mechanism of these effects is rather complex. Pluronics, in
contrast to the majority of low molecular mass inhibitors of drug
eﬄux transporters that are designed to interact specifically with
the transport system protein, are known to perform a wide range
of activities. They inhibit P-gp and MRP drug eﬄux proteins
(Batrakova and Kabanov, 2008) through interaction with MDR
cell membranes by decreasing the membrane microviscosity and
inhibiting the P-gp and MRP ATPase activity (Batrakova et al.,
2001, 2003). They are also known to inhibit respiratory chain
complexes in the mitochondria of MDR cells. This diminishes
ATP and depletes MDR cells of energy (Batrakova et al.,
2001). Furthermore, Pluronics causes a sharp reduction in GSH
and GST activity, thereby inhibiting glutathione/glutathione S-
transferase (GSH/GST) resistant mechanisms (Batrakova et al.,
2003). In addition, they may improve the bioavailability of
drugs within resistant cells by attenuating their sequestration
in acidic vesicles (Venne et al., 1996). Lastly, Pluronics have
been found to reduce membrane potential in the mitochondria
of MDR cells. This causes an overall increase in pro-apoptotic
signaling and decrease in anti-apoptotic cellular defense of
MDR cells via increase in cytochrome C release (Minko
et al., 2005). Surprisingly, Pluronics appear to be selective
with respect to the MDR cell phenotype despite their rather
simple structure and lack of precise spatial arrangement
of pharmacophoric groups (Batrakova et al., 2001). This is
most noticeably seen in ATP depletion by Pluronics, which
correlates with the level of drug eﬄux transporters expression
in the resistant cells (Batrakova et al., 2003). Of course, the
more complete understanding of these issues is necessary for
the future development of drug delivery system based on
polymer surfactants. Nevertheless, this strategy has a potential
in developing novel modalities for delivery of various drug
to the brain, including HPIs to eradicate HIV virus in the
brain. Recent development on long acting nanoparticle against
both HIV-1 and TB suggested that gallium-based anti-HIV and
TB nanodrug can control HIV and TB replication in dual
infected human macrophages. However, whether it can bypass
MRP eﬄux has not been tested so far (Narayanasamy et al.,
2015).
Conclusion
The MRP family forms the major eﬄux system involved in
eﬄux transport of anti-HIV drug out of cells. The expression
profile of certain MRPs in the cell membrane has not been
well characterized. While the presence of MRP1-MRP9 has
been established in different cell lines (Borst et al., 2000), the
function and activity of most members remains speculative.
Understanding the role of MRP family is crucial to establishing
effective HAART, as PI and NRTIs are good substrates for MRPs.
Published reports suggest that oxidative stress, alteration of
glutathione metabolism and activation of the MAP kinase can be
involved in MRP expression (Guan et al., 2004; Hayashi et al.,
2006). Hayashi et al., 2006 also suggested that HIV transcription
regulator, Tat protein can specifically up-regulate MRP1 which
may contribute to the development of resistance to HAART. Up-
regulation of MRP1 also has the potential of increasing the eﬄux
of anti-TB drugs. It is important to focus to research on signaling
cascade that triggers the altered expression ofMRPs. The fact that
MRPs are present in different forms in different cell membranes
makes studying them difficult. Inhibiting specific MRPs—even
for short periods of time—is not tolerated well in patients.
Increased understanding in this field will enable researchers to
design more focused methods to inhibit HIV replication.
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